---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-22-000016"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:12:59.351734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance

## Summary
- Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).
- Biktarvy sales $2.6B (+28% YoY); oncology sales $527M (+71% YoY) driven by cell therapy and Trodelvy.
- HIV product sales $4.2B (+7% YoY); HCV sales $448M (-18% YoY); Veklury sales $445M (-46% YoY).
- FY guidance raised: product sales $24.5-25.0B (prev $23.8-24.3B); non-GAAP EPS $6.35-6.75 (prev $6.20-6.70).
- Operating cash flow $1.8B in Q2; cash & equivalents $7.0B as of June 30, 2022.

## SEC filing metadata
- accession: 0000882095-22-000016
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/0000882095-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/gild-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-22-000016
- JSON: https://secwatch.observer/filing/0000882095-22-000016.json
- Plain text: https://secwatch.observer/filing/0000882095-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.